Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 7/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.72 |
| ▸ | ADRA2B | P18089 | 6/20 | 0.72 |
| ▸ | LMNA | P02545 | 4/20 | 0.72 |
| ▸ | HRH2 | P25021 | 2/20 | 0.72 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.72 |
| ▸ | HTR1D | P28221 | 4/20 | 0.58 |
| ▸ | HTR1B | P28222 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.47 |
| ▸ | CFB | P00751 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6054524 | 0.84 | ADRA2A (0.72) | ADRA2AADRA2CADRA1AADRA2BLMNA | |
| SCHEMBL2615415 | 0.84 | ADRA2A (0.72) | ADRA2AADRA2CADRA1AADRA2BLMNA | |
| Tizanidine SCHEMBL60334 | 0.84 | ADRA2A (1.00) | ADRA2AADRA2CADRA1AADRA2BLMNA | |
| Tizanidine SCHEMBL20769844 | 0.84 | ADRA2A (1.00) | ADRA2AADRA2CADRA1AADRA2BLMNA | |
| SCHEMBL6054569 | 0.83 | ADRA2A (0.67) | ADRA2AADRA2CADRA1AADRA2BLMNA | |
| SCHEMBL6054568 | 0.83 | ADRA2A (0.67) | ADRA2AADRA2CADRA1AADRA2BLMNA | |
| Tizanidine SCHEMBL8312917 | 0.83 | ADRA2A (0.77) | ADRA2AADRA2CADRA1AADRA2BLMNA | |
| Tizanidine SCHEMBL23498010 | 0.83 | ADRA2A (0.97) | ADRA2AADRA2CADRA1AADRA2BLMNA | |
| Tizanidine SCHEMBL41199 | 0.83 | ADRA2A (1.00) | ADRA2AADRA2CADRA1AADRA2BLMNA | |
| SCHEMBL6054520 | 0.83 | ADRA2A (0.60) | ADRA2AADRA2CADRA1AADRA2BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023062201-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF TIZANIDINE | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2023-04-20 | — | — | WO | disclosed |
| US-20060063813-A1 | Organic compounds | CRAWLEY PATRICK E | 2006-03-23 | — | — | US | disclosed |
| EP-1556042-A2 | COMBINATIONS OF BENZODITHIAZOLES AND COX-2 INHIBITORS FOR THE TREATMENT OF PAIN | Novartis AG (CH) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004035030-A2 | COMBINATIONS OF BENZODITHIAZOLES AND COX-2 INHIBITORS FOR THE TREATMENT OF PAIN | NOVARTIS AG (CH) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063813-A1 | Organic compounds | PTGES2, PTGS2, PTGER2 | ADRA2A 1059/4885ADRA2C 525/4885ADRA1A 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.